Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GWRS vs AARD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GWRS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

GWRS Overall Winner 6-Pillar Tally: GWRS 5 – 1 AARD Matrix Metrics: GWRS 10 – 0 AARD

As of Nov 20, 2026, Global Water Resources, Inc. (GWRS) is the stronger overall head-to-head candidate over Aardvark Therapeutics, Inc. (AARD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GWRS carries a Unified Composite Score of 52.7/100 (HOLD) at $6.40 (58.2x Forward P/E, 12.6% operating margin), whereas AARD carries 45.9/100 (HOLD) at $0.92 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: GWRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.3); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GWRS vs AARD
GWRS NASDAQ Head-to-Head Winner
Global Water Resources, Inc.
Water Supply
$6.40
+0.0% 1D
Market Cap $191.6M
TTM Revenue $61M
Forward P/E 58.2x
Beta / 30D Vol 0.30β · 40% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 55.0 Fund 53.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.1%), weak momentum, RSI 26
RSI-14: 26.3 · SMA20: $7.24 · SMA50: $7.77
AARD NASDAQ
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.92
-7.74% 1D
Market Cap $21.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.84β · 284% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.6%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.25 · SMA50: $3.35

6-Pillar Scorecard Institutional Category Breakdown (GWRS 5 – 1 AARD)

Columns: Metric · GWRS · AARD
1. Valuation Multiples GWRS
Forward P/E 58.2x N/M
Trailing P/E 80.0x N/M
PEG Ratio 2.89x N/M
EV / Revenue 3.1x N/M
2. Growth & Scale GWRS
Revenue Growth (YoY) +5.0% +0.0%
Earnings Growth (YoY) -50.0% +0.0%
TTM Revenue (USD) $61M N/A
Market Cap $191.6M $21.9M
3. Profitability & Quality GWRS
Gross Margin 71.7% N/A
Operating Margin 12.6% 0.0%
Net Profit Margin 4.0% 0.0%
Return on Equity (ROE) 2.6% -66.0%
4. Balance Sheet & Cash Flow GWRS
Cash Generation (TTM) $26M EBITDA N/A
Cash Flow Margin 42.3% EBITDA Mgn N/A
Net Cash / Leverage $3.13 Book/Sh · 2.6% ROE $73M Net Cash
Dividend Yield 4.66% None (0.00%)
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 60.9% (100th %ile) 147.3% (26th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat GWRS
OpEx & R&D Intensity 59.1% of Rev ($36M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Utilities - Regulated Water Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GWRS (10) vs AARD (0)
Institutional Metric GWRS AARD Criterion Row Edge
Market Capitalization
Scale
$191.6M $21.9M Larger Scale GWRS
Trailing P/E Ratio
Valuation
80.0x N/M Lower Multiple GWRS
Forward P/E Ratio
Valuation
58.2x N/M Lower Multiple GWRS
Revenue Growth (YoY)
Growth
+5.0% +0.0% Higher Growth GWRS
Operating Margin (TTM)
Profitability
12.6% 0.0% Higher Margin GWRS
Net Profit Margin
Profitability
4.0% 0.0% Higher Margin GWRS
Return on Equity (ROE)
Capital Efficiency
2.6% -66.0% Higher ROE GWRS
52-Week Range Position
Momentum
2% ($6–$10) 0% ($1–$17) Stronger Trend GWRS
Beta / 30D Volatility
Risk Regime
0.30β · 40% Vol 3.84β · 284% Vol Lower Realized Risk GWRS
Unified Institutional Score
Composite Signal
52.7 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite GWRS
Trailing 12M Revenue (USD)
Operating Scale
$61M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.89x PEG · 3.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$26M EBITDA ($3.13 Book/Sh · 2.6% ROE) N/A ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GWRS +57.65 pp
GWRS: -18.99% · AARD: -76.64%
3M Horizon GWRS +54.97 pp
GWRS: -31.62% · AARD: -86.59%
6M Horizon GWRS +68.32 pp
GWRS: -11.36% · AARD: -79.68%
1Y Horizon GWRS +64.91 pp
GWRS: -26.27% · AARD: -91.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GWRS vs AARD. Trailing 12-month operating profitability (GWRS 12.6% vs AARD 0.0%) and valuation multiples (GWRS 58.2x vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GWRS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$61M
Gross Margin71.7%
Op. Margin12.6%
ROE / Fwd P/E2.6% · 58.2x
AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GWRS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 60.9%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GWRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GWRS Moat Profile Cyclical / Execution-Driven Positioning
Utilities - Regulated Water Operator
Competes within the Utilities - Regulated Water value chain with $191.6M market capitalization and 12.6% operating margin.
OpEx & R&D Reinvestment 59.1% of Rev ($36M)
90D Engineering Disclosures 0 Published
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $21.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GWRS vs AARD Key Questions & Quantitative Answers

As of Nov 20, 2026, Global Water Resources, Inc. (GWRS) is the stronger overall head-to-head candidate over Aardvark Therapeutics, Inc. (AARD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GWRS carries a Unified Composite Score of 52.7/100 (HOLD) at $6.40 (58.2x Forward P/E, 12.6% operating margin), whereas AARD carries 45.9/100 (HOLD) at $0.92 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: GWRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.3); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GWRS leads the Growth & Scale pillar: GWRS posts +5.0% YoY revenue growth and -50.0% YoY earnings growth on $61M TTM revenue (71.7% gross margin, 12.6% operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GWRS generates $61M in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, GWRS deploys 59.1% of Rev ($36M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.

GWRS screens cheaper on headline valuation multiples. GWRS trades at 58.2x Forward P/E, 80.0x Trailing P/E, 2.89x PEG, and 3.1x EV/Revenue (42.3% EBITDA margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GWRS (2.6% ROE) versus AARD (-66.0% ROE) capital efficiency.

In options market volatility and institutional positioning, GWRS carries 60.9% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.30β · 40% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.84β · 284% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.